Clearpoint Price To Sales Ratio from 2010 to 2024
| CLPT Stock | USD 12.37 0.26 2.15% |
Price To Sales Ratio | First Reported 2010-12-31 | Previous Quarter 6.97430138 | Current Value 7.13 | Quarterly Volatility 6.21835014 |
Check Clearpoint Neuro financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Clearpoint Neuro's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.5 M, Interest Expense of 366.7 K or Selling General Administrative of 7.5 M, as well as many indicators such as Price To Sales Ratio of 7.13, Dividend Yield of 0.0 or PTB Ratio of 8.29. Clearpoint financial statements analysis is a perfect complement when working with Clearpoint Neuro Valuation or Volatility modules.
Clearpoint | Price To Sales Ratio |
Latest Clearpoint Neuro's Price To Sales Ratio Growth Pattern
Below is the plot of the Price To Sales Ratio of Clearpoint Neuro over the last few years. Price to Sales Ratio is figured by comparing Clearpoint Neuro stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Clearpoint Neuro sales, a figure that is much harder to manipulate than other Clearpoint Neuro multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. It is a valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period. Clearpoint Neuro's Price To Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Clearpoint Neuro's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 11.21 X | 10 Years Trend |
|
Price To Sales Ratio |
| Timeline |
Clearpoint Price To Sales Ratio Regression Statistics
| Arithmetic Mean | 8.79 | |
| Geometric Mean | 6.75 | |
| Coefficient Of Variation | 70.75 | |
| Mean Deviation | 5.16 | |
| Median | 6.97 | |
| Standard Deviation | 6.22 | |
| Sample Variance | 38.67 | |
| Range | 19.4949 | |
| R-Value | 0.05 | |
| Mean Square Error | 41.56 | |
| R-Squared | 0 | |
| Significance | 0.87 | |
| Slope | 0.06 | |
| Total Sum of Squares | 541.35 |
Clearpoint Price To Sales Ratio History
About Clearpoint Neuro Financial Statements
Clearpoint Neuro shareholders use historical fundamental indicators, such as Price To Sales Ratio, to determine how well the company is positioned to perform in the future. Although Clearpoint Neuro investors may analyze each financial statement separately, they are all interrelated. The changes in Clearpoint Neuro's assets and liabilities, for example, are also reflected in the revenues and expenses on on Clearpoint Neuro's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Price To Sales Ratio | 6.97 | 7.13 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.